Vanda Pharmaceuticals, Inc. Investigated by the Portnoy Law Firm
Vanda Pharmaceuticals Inc. (VNDA)
Last vanda pharmaceuticals inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=196233&p=irol-irhome
Company Research
Source: GlobeNewswire
LOS ANGELES, April 20, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Vanda Pharmaceuticals, Inc., (“Vanda" or the "Company") (NASDAQ: VNDA) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/vanda-pharmaceuticals-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. Vanda’s stock price plummeted $1.20 per share, or 14.05%, to close at $7.34 per share on January 8, 2026, thereby injuring investors. This sharp market contraction was triggered by a January 8, 2026, announcement regarding a significant regulatory setback for the Company’s primary therapeutic expansion. The primary driver of the valuation coll
Show less
Read more
Impact Snapshot
Event Time:
VNDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNDA alerts
High impacting Vanda Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
VNDA
News
- Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines [Yahoo! Finance]Yahoo! Finance
- Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines [TheStreet.com]TheStreet.com
- Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review TimelinesPR Newswire
- Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists [TheStreet.com]TheStreet.com
- Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor AgonistsPR Newswire
VNDA
Earnings
- 2/11/26 - Miss
VNDA
Analyst Actions
- 2/23/26 - HC Wainwright
VNDA
Sec Filings
- 4/13/26 - Form 3
- 4/13/26 - Form 3
- 4/2/26 - Form 8-K
- VNDA's page on the SEC website